# Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)

> **NCT03795311** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Centre Georges Francois Leclerc** · enrollment: 32 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** FOLFIRINOX Bevacizumab

## Key facts

- **NCT ID:** NCT03795311
- **Lead sponsor:** Centre Georges Francois Leclerc
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-07
- **Primary completion:** 2023-01-16
- **Final completion:** 2025-07-16
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03795311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03795311, "Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03795311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*